Key result
Higher serum tryptase levels show no link to ventricular remodeling one month post-ACS.
Why the study?
Tryptase is suggested to play a significant role in the pathophysiology of ACS and subsequent ventricular remodeling, but its correlation with post-ACS ventricular remodeling needed evaluation.
Does higher serum tryptase level correlate with ventricular remodeling in patients with acute coronary syndrome after 1 month?
Cohort (n=25)
Does higher serum tryptase level correlate with ventricular remodeling in patients with acute coronary syndrome after 1 month?
p-value: p=0.668
Serum tryptase levels measured at admission do not significantly correlate with echocardiographic signs of ventricular remodeling at one month in patients with acute coronary syndrome.
Admission tryptase adds no value to post-ACS remodeling risk assessment; leaves open any mast cell role pending larger studies.
Tryptase, an enzyme secreted by mast cell, is suggested to play a significant role in the pathophysiology of acute coronary syndrome (ACS) and subsequent ventricular remodeling (VR). This study aimed to understand the correlation between the serum level of tryptase and VR in patients with ACS after one month of onset. Sampling method was total sampling where patients with ACS enrolled in the study were allocated into two groups based on their serum tryptase level, lower level (n=13) and higher level (n=12) groups. All subjects underwent echocardiography examination on admission to obtain their initial data and they were reevaluated one month later for the signs of VR. The occurrences of VR were examined by echocardiography with LVEDP and LVESV used as the VR parameters. Fisher Exact Test showed no significant difference between both groups in term of VR (p=0.668). The contingency coefficient analysis revealed no correlation between tryptase level and the occurrence of VR (p=0.113). However, the multiple regression analysis suggested that LVEDP and LVESV demonstrated multicollinearity to tryptase and VR. Although the current study concluded no correlation between tryptase level and VR following ACS, a prospective study with longer follow-up time is expected to gain more information.
No takes yet. Share an insight, caveat, or question.
Yuni et al. (2020) conducted a cohort in Acute coronary syndrome (n=25). Higher serum tryptase level vs. Lower serum tryptase level was evaluated on Ventricular remodeling (p=0.668). Higher serum tryptase levels showed no significant difference compared to lower levels in terms of ventricular remodeling at one month following acute coronary syndrome (p=0.668).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: